The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara
Abstract
Heterologous prime-boost immunization strategies can evoke powerful T cell immune responses and may be of value in developing an improved tuberculosis vaccine. We show that recombinant modified vaccinia virus Ankara, expressing Mycobacterium tuberculosis Ag 85A (M.85A), strongly boosts bacille Calmette-Guérin (BCG)-induced Ag 85A specific CD4+ and CD8+ T cell responses in mice. A comparison of intranasal (i.n.) and parenteral immunization of BCG showed that while both routes elicited comparable T cell responses in the spleen, only i.n. delivery elicited specific T cell responses in the lung lymph nodes, and these responses were further boosted by i.n. delivery of M.85A. Following aerosol challenge with M. tuberculosis, i.n. boosting of BCG with either BCG or M.85A afforded unprecedented levels of protection in both the lungs (2.5 log) and spleens (1.5 log) compared with naive controls. Protection in the lung correlated with the induction of Ag 85A-specific, IFN-γ-secreting T cells in lung lymph nodes. These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flynn, J. L., & Chan, J. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.93 · Cited by 2,155
Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature
Colditz, G. A. (1994) · JAMA · doi:10.1001/jama.1994.03510330076038 · Cited by 1,918
Variation in protection by BCG: implications of and for heterologous immunity
Fine, P. E. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92348-9 · Cited by 1,380
Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L., & Hill, A. V. S. (1998) · Nature Medicine · doi:10.1038/nm0498-397 · Cited by 644
Self-citationImmunogenicity and protective efficacy of a tuberculosis DNA vaccine
Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Randall Deck, R., DeWitt, C. M., Orme, I. M., Baldwin, S., D'Souza, C., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-893 · Cited by 629
EPIDEMIOLOGY OF TUBERCULOSIS IN THE UNITED STATES
RIEDER, H. L., CAUTHEN, G. M., COMSTOCK, G. W., & SNIDER, D. E. (1989) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036046 · Cited by 447
Horwitz, M. A., Harth, G., Dillon, B. J., & Masleša-Galić, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250480397 · Cited by 436
Chackerian, A. A., Alt, J. M., Perera, T. V., Dascher, C. C., & Behar, S. M. (2002) · Infection and Immunity · doi:10.1128/iai.70.8.4501-4509.2002 · Cited by 407
Control of latentMycobacterium tuberculosis infection is dependent on CD8 T cells
van Pinxteren, L. A. H., Cassidy, J. P., Smedegaard, B. H. C., Agger, E. M., & Andersen, P. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3689::aid-immu3689>3.0.co;2-4 · Cited by 366
Human cytolytic and interferon γ-secreting CD8+T lymphocytes specific for Mycobacterium tuberculosis
Lalvani, A., Brookes, R., Wilkinson, R. J., Malin, A. S., Pathan, A. A., Andersen, P., Dockrell, H., Pasvol, G., & Hill, A. V. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.270 · Cited by 361
Self-citationStrategies for designing and optimizing new generation vaccines
Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001) · Nature Reviews Immunology · doi:10.1038/35105075 · Cited by 334
Does the efficacy of BCG decline with time since vaccination?
Sterne, J. A. C., Rodrigues, L. C., & Guedes, I. N. (1998) · PubMed · Cited by 310
Gallichan, W. S., & Rosenthal, K. L. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1879 · Cited by 238
Dendritic Cells Are Host Cells for Mycobacteria In Vivo That Trigger Innate and Acquired Immunity
Jiao, X., Lo-Man, R., Guermonprez, P., Fiette, L., Dériaud, E., Burgaud, S., Gicquel, B., Winter, N., & Leclerc, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1294 · Cited by 221
Gonzalez-Juarrero, M., Turner, O. C., Turner, J., Marietta, P., Brooks, J. V., & Orme, I. M. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1722-1728.2001 · Cited by 221
Langermans, J. A. M., Andersen, P., van Soolingen, D., Vervenne, R. A. W., Frost, P. A., van der Laan, T., van Pinxteren, L. A. H., van den Hombergh, J., Kroon, S., Peekel, I., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201404898 · Cited by 204
Macrophages are a significant source of type 1 cytokines during mycobacterial infection
Wang, J., Wakeham, J., Harkness, R., & Xing, Z. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6224 · Cited by 196
Local Immune Responses Correlate with Presentation and Outcome in Tuberculosis
CONDOS, R., ROM, W. N., LIU, Y. M., & SCHLUGER, N. W. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.3.9705044 · Cited by 195
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
Stittelaar, K. J., Kuiken, T., de Swart, R. L., van Amerongen, G., Vos, H. W., Niesters, H. G. M., van Schalkwijk, P., van der Kwast, T., Wyatt, L. S., Moss, B., et al. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00075-5 · Cited by 188
Dupuis, S., Döffinger, R., Picard, C., Fieschi, C., Altare, F., Jouanguy, E., Abel, L., & Casanova, J. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17810.x · Cited by 180
Serbina, N. V., & Flynn, J. L. (1999) · Infection and Immunity · doi:10.1128/iai.67.8.3980-3988.1999 · Cited by 174
Chackerian, A. A., Perera, T. V., & Behar, S. M. (2001) · Infection and Immunity · doi:10.1128/iai.69.4.2666-2674.2001 · Cited by 173
Belyakov, I. M., Moss, B., Strober, W., & Berzofsky, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4512 · Cited by 168
Denis, O., Tanghe, A., Palfliet, K., Jurion, F., van den Berg, T.-P., Vanonckelen, A., Ooms, J., Saman, E., Ulmer, J. B., Content, J., et al. (1998) · Infection and Immunity · doi:10.1128/iai.66.4.1527-1533.1998 · Cited by 167
Topham, D. J., Castrucci, M. R., Wingo, F. S., Belz, G. T., & Doherty, P. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6983 · Cited by 155
Harth, G., Lee, B. Y., Wang, J., Clemens, D. L., & Horwitz, M. A. (1996) · Infection and Immunity · doi:10.1128/iai.64.8.3038-3047.1996 · Cited by 139
Barclay, W. R., Busey, W. M., Dalgard, D. W., Good, R. C., Janicki, B. W., Kasik, J. E., Ribi, E. E., Ulrich, C. E., & WOLINSKY, E. (1973) · PubMed · doi:10.1164/arrd.1973.107.3.351 · Cited by 138
Influenza Virus Lung Infection Protects from Respiratory Syncytial Virus–Induced Immunopathology
Walzl, G., Tafuro, S., Moss, P. A. H., Openshaw, P., & Hussell, T. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1317 · Cited by 137
McShane, H., Behboudi, S., Goonetilleke, N. P., Brookes, R. H., & Hill, A. V. S. (2002) · Infection and Immunity · doi:10.1128/iai.70.3.1623-1626.2002 · Cited by 123
Self-citationBelz, G. T., Altman, J. D., & Doherty, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13812 · Cited by 108
Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules
Eo, S. K., Gieryńska, M. M., Abo-Kamar, A. M., & Rouse, B. T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5473 · Cited by 104
Bruyn, J. D., Huygen, K., Bosmans, R., Fauville‐Dufaux, M., Lippens, R., Vooren, J. V., Falmagne, P., Weckx, M., Wiker, H. G., Harboe, M., et al. (1987) · Microbial Pathogenesis · doi:10.1016/0882-4010(87)90077-5 · Cited by 101
Wyatt, L. S. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00257-1 · Cited by 77
Lyadova, I. V., Eruslanov, E. B., Khaidukov, S. V., Yeremeev, V., Majorov, K. B., Pichugin, A. V., Nikonenko, B. V., Kondratieva, T. K., & Apt, A. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5921 · Cited by 76
Smith, S. M., Klein, M. R., Malin, A. S., Sillah, J. S., Huygen, K., Andersen, P. L., McAdam, K. P. W. J., & Dockrell, H. M. (2000) · Infection and Immunity · doi:10.1128/iai.68.12.7144-7148.2000 · Cited by 74
Aerogenic BCG Vaccination Against Tuberculosis in Animal and Human Subjects
Rosenthal, S. R., McEnery, J. T., & Raisys, N. (1968) · Journal of Asthma Research · doi:10.3109/02770906809100348 · Cited by 59
Lehmann, C., Wilkening, A., Leiber, D., Markus, A. M. A., Krug, N., Pabst, R., & Tschernig, T. (2001) · The Anatomical Record · doi:10.1002/ar.1163 · Cited by 52
Palendira, U., Bean, A. G. D., Feng, C. G., & Britton, W. J. (2002) · Infection and Immunity · doi:10.1128/iai.70.3.1410-1416.2002 · Cited by 51
Cited by
Cell-Mediated Immune Responses in Tuberculosis
Cooper, A. M. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132703 · Cited by 1,162
Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., Shea, J. E., McClain, J. B., Hussey, G. D., Hanekom, W. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60177-4 · Cited by 1,049
Self-citationThe success and failure of BCG — implications for a novel tuberculosis vaccine
Andersen, P., & Doherty, T. M. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1211 · Cited by 788
McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A., & Hill, A. V. S. (2004) · Nature Medicine · doi:10.1038/nm1128 · Cited by 570
Self-citationGrode, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24617 · Cited by 557
Metadata
- Authors
- Goonetilleke, N. P., McShane, H., Hannan, C. M., Anderson, R. J., Brookes, R. H., & Hill, A. V. S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-01
- Volume
- 171
- Issue
- 3
- Pages
- 1602-1609
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1607937732
- Cited by
- 360
- References
- 40
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.